This article has been updated from a previous version to clarify the company's reimbursement goals for 2013.

SAN FRANCISCO (GenomeWeb News) – Sequenom Chairman and CEO Harry Hixson on Wednesday expressed confusion over Illumina's decision to acquire Verinata for a price that could climb to $450 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.